MBBS, MD - Medicine, DM - Medical Oncology
25 Years Experience Overall (15 years as specialist)
Dr. Hari Menon is a senior consultant at Cytecare Cancer Hospital who has been in the field of medical oncology for the past 18 years, with special focus in the specialized field of haematological malignancies, which caters to both leukemia (blood cancers) and lymphomas (malignancies associated with the lympho reticular system). He has since worked at the Tata Memorial Cancer Centre, Mumbai, as consultant and Professor of Medical Oncology for the past 12 years. He has featured consistently among the best oncologists in the country, and has been nominated on two occasions among Mumbai’s Top Docs in peer-nominated surveys.Dr. Menon has been in academia right from the time he completed his post-graduation. During his tenure in academia, he has been actively involved in clinical research and served as Principal Investigator on several clinical trials, both at national and global levels. He has a deep interest in designing studies in oncology and has been involved with the same at the institutional, national and global levels. He has been a member of the ICMR (Indian Council of Medical Research) task force for formulating guidelines in haematological malignancies. He was the recipient of the ACORD (Australia & Asia Pacific Clinical Oncology Research Development) and INDOX (India Oxford clinical research) training. He is also a national faculty for ACORD and CREDO in India, disciplines which are involved in training researchers and oncologists in the field of clinical research.Dr. Menon has been credited with over 50 publications, and numerous presentations and book chapters. He is a member of the American society of hematology and the European hematology association. Dr. Menon is a Reviewer for Indian and International peer-reviewed oncology journals and has been an invited member on the advisory board for drug development by several multi-national pharmaceutical companies. He is also associated with cancer patient advocacy and support groups, and with agencies striving to make cancer care widely available to patients.